Get started
Author

Jan Hendrik Grothe

Observed names: Jan Grothe, Jan H Grothe, Jan H. Grothe, Jan-Hendrik Grothe
Observed institutions: University of Cologne, Univerzitetski Klinički Centar Srbije, German Center for Infection Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University Hospital Cologne, Virginia Tech
ORCID: 0000-0001-8498-231X
Observed ORCID: 0000-0001-8498-231X
OpenAlex ID: A5005050859
Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM
2025 · Oliver A Cornely, Rosanne Sprute, et al. · The Lancet Infectious Diseases · 411
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
2024 · Jon Salmanton-García, Francesco Marchesi, et al. · EClinicalMedicine · 35
PDF
Quantification of the Mycotoxin Deoxynivalenol (DON) in Sorghum Using GC-MS and a Stable Isotope Dilution Assay (SIDA)
2019 · Nicole McMaster, Bhupendra Acharya, et al. · Food Analytical Methods · 23
Monkeypox diagnostic and treatment capacity at epidemic onset: A VACCELERATE online survey
2022 · Jan Hendrik Grothe, Oliver A. Cornely, et al. · Journal of Infection and Public Health · 16
PDF
Circulatory Inflammatory Proteins as Early Diagnostic Biomarkers for Invasive Aspergillosis in Patients with Hematologic Malignancies—an Exploratory Study
2024 · Robina Aerts, Isis Ricaño-Ponce, et al. · Mycopathologia · 13
PDF
Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)
2023 · Julia M. Neuhann, Jannik Stemler, et al. · Vaccine · 8
Monkeypox in children and adult women in Europe: Results from a flash VACCELERATE pilot survey
2022 · Jan Hendrik Grothe, Oliver A. Cornely, et al. · Enfermedades Infecciosas y Microbiología Clínica · 7
PDF
Survival after cryptococcosis in Germany: A retrospective multicenter cohort study of patients diagnosed between 2004 and 2021
2024 · Johanna Kessel, Anna-Catharina Rossaert, et al. · International Journal of Medical Microbiology · 5
Reason and reality—identifying barriers to patient enrolment for clinical trials in invasive candidiasis
2022 · Rosanne Sprute, Jan H Grothe, et al. · Journal of Antimicrobial Chemotherapy · 5
PDF
The Cologne ECMM Excellence Center: A Two-Year Analysis of External Consultation Service for Invasive Fungal Infections
2024 · Jon Salmanton-García, Philipp Koehler, et al. · Mycopathologia · 4
PDF
Infektionen bei Patient*innen mit Akuter Myeloischer Leukämie
2023 · Sabine Ehrlich, Karsten Spiekermann, et al. · DMW - Deutsche Medizinische Wochenschrift · 4
Monkeypox in children and adult women in Europe: Results from a flash VACCELERATE pilot survey
2023 · Jan Hendrik Grothe, Oliver A. Cornely, et al. · Enfermedades infecciosas y microbiologia clinica (English ed ) · 3
Comment on: Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching
2022 · Jan Grothe, Rosanne Sprute, et al. · Journal of Antimicrobial Chemotherapy · 3
PDF
The 2025 EQUAL Pneumocystis Score—an ECMM tool to measure QUALity in Pneumocystis pneumonia management
2025 · Luise Haensel, Rosanne Sprute, et al. · JAC-Antimicrobial Resistance · 1
PDF
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)
2024 · Jannik Stemler, Lusine Yeghiazaryan, et al. · International Journal of Infectious Diseases · 1
PDF
2383. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: a randomised trial in adults ≥75 years (EU-COVAT-1) from the VACCELERATE consortium
2023 · Jon Salmanton-Garcia, Julia M Neuhann, et al. · Open Forum Infectious Diseases · 1
PDF
Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)
2023 · Julia Neuhann, Jannik Stemler, et al. · SSRN Electronic Journal · 1
P422 EQUAL PCP Score 2022—an ECMM score derived from current guidelines to measure QUAlity of clinical Pneumocystis Pneumonia management
2022 · Jan Grothe · Medical Mycology · 1
PDF
Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
2026 · Ilana Reinhold, Isabel Cristina Ramirez-Sanchez, et al. · EClinicalMedicine
Immunogenicity, Reactogenicity and Safety to Assess Booster Vaccinations with BNT162b2 or Full-Dose mRNA-1273 in Adults ≥75 Years (EU-COVAT-1-AGED) – Final Report
2025 · Jannik Stemler, Lusine Yeghiazaryan, et al. · SSRN Electronic Journal
Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)
2023 · Jannik Stemler, Lusine Yeghiazaryan, et al. · SSRN Electronic Journal
Works count: 21
Citation count: 542
H-index: 7
I10-index: 5
Year
Topic
Type